Abstract.
Several studies have suggested a positive correlation between heat shock protein (hsp) expression and tumor immunogenicity. Independently, many studies have shown that hsp purified from tumors can be used as a tumor-specific vaccine. In this study, we have explored the connection between hsp expression and anti-tumor immunity by transducing murine CT26 colon carcinoma cells with the cDNA of a major hsp, i.e. hsp110. We have shown that over-expression of hsp110 has no effect on CT26 tumor cell growth in vitro, and does not inhibit their anchorage-independent growth capacity. However, in situ, hsp110 over-expressing CT26 tumor (CT26-hsp110) grew at a significantly reduced rate as compared to the wild-type CT26 tumor in immunocompetent mice. Moreover, immunization of mice with inactivated CT26-hsp110 cells significantly inhibited the growth of wild-type CT26 tumor. This immunity was associated with an increased frequency of tumor-specific T cells after vaccination. An in vivo antibody depletion assay demonstrated that inactivated CT26-hsp110 cells elicited anti-tumor responses involving CD8+ T cells and natural killer (NK) cells, but not CD4+ T cells. Lastly, the effect of the addition of granulocyte–macrophage colony stimulating factor (GM–CSF) to these vaccine formulations was determined. Mice immunized with irradiated CT26-hsp110 cells combined with GM–CSF-producing bystander cells revealed a complete inhibition of CT26 tumor growth, indicating a synergy between inactivated CT26-hsp110 vaccine activity and GM–CSF. These observations demonstrate that manipulation of hsp110 expression in tumors, specifically when combined with GM–CSF, represents a potentially powerful approach to cancer vaccine formulation.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Wang, XY., Li, Y., Manjili, M.H. et al. Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor. Cancer Immunol Immunother 51, 311–319 (2002). https://doi.org/10.1007/s00262-002-0287-1
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00262-002-0287-1